Brokerages Set AtriCure, Inc. (NASDAQ:ATRC) PT at $50.89

Key Points

• AtriCure, Inc. received a consensus rating of "Buy" from nine analysts, with an average price target of $50.89.
• Insider transactions include Vinayak Doraiswamy and Regina E. Groves selling a combined total of 12,452 shares for approximately $445,333 in the last 90 days.
• AtriCure reported a revenue increase of 17.1% year-over-year, with the latest quarterly earnings beating analyst estimates by $0.13 per share.

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have earned a consensus recommendation of "Buy" from the nine research firms that are currently covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $50.8889.

Several research firms have recently commented on ATRC. UBS Group lowered their target price on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Needham & Company LLC lifted their target price on AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, July 30th. JMP Securities reissued a "market outperform" rating and issued a $60.00 target price on shares of AtriCure in a research note on Wednesday, April 30th. BTIG Research set a $54.00 target price on AtriCure in a research note on Wednesday, July 30th. Finally, Wall Street Zen raised AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd.

Insider Activity

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $36.58, for a total value of $91,450.00. Following the transaction, the insider directly owned 71,872 shares in the company, valued at $2,629,077.76. This trade represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Sven Wehrwein sold 5,000 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $37.00, for a total value of $185,000.00. Following the completion of the transaction, the director owned 34,374 shares in the company, valued at $1,271,838. This represents a 12.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,952 shares of company stock valued at $546,733. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in shares of AtriCure by 6.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company's stock worth $162,000 after purchasing an additional 312 shares during the last quarter. Invesco Ltd. boosted its position in shares of AtriCure by 0.8% in the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock worth $1,334,000 after purchasing an additional 334 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of AtriCure by 5.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company's stock worth $246,000 after purchasing an additional 385 shares during the last quarter. State of Wyoming boosted its position in shares of AtriCure by 21.9% in the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after purchasing an additional 446 shares during the last quarter. Finally, LPL Financial LLC boosted its position in shares of AtriCure by 5.4% in the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock worth $350,000 after purchasing an additional 584 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Price Performance

ATRC stock traded down $0.57 during midday trading on Friday, reaching $37.30. 205,617 shares of the company's stock traded hands, compared to its average volume of 638,748. The company has a 50-day simple moving average of $33.38 and a two-hundred day simple moving average of $33.86. AtriCure has a 1-year low of $25.24 and a 1-year high of $43.11. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -48.44 and a beta of 1.61. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The firm had revenue of $136.14 million during the quarter, compared to analysts' expectations of $130.17 million. During the same period last year, the firm posted ($0.17) EPS. The business's revenue was up 17.1% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. On average, analysts anticipate that AtriCure will post -0.6 earnings per share for the current year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.